Concept information
Terme préférentiel
Alefacept
Type
-
mesh:Descriptor
Définition
- A recombinant human fusion protein of LFA-3 antigen and immunoglobulin IGG1 that binds to CD2 ANTIGENS on memory T-LYMPHOCYTES, preventing their activation and proliferation. It is used in the management of moderate to severe chronic plaque PSORIASIS.
Concept générique
Synonyme(s)
- 222535-22-0 (Alefacept)
- ELK3V90G6C
- LFA-3 IgG1 Fusion Protein
- LFA-3 IgG(1) Fusion Protein
Qualificatif(s) autorisé(s)
- administration & dosage (Qualifier)
- adverse effects (Qualifier)
- agonists (Qualifier)
- analysis (Qualifier)
- antagonists & inhibitors (Qualifier)
- biosynthesis (Qualifier)
- blood (Qualifier)
- cerebrospinal fluid (Qualifier)
- chemical synthesis (Qualifier)
- chemistry (Qualifier)
- classification (Qualifier)
- deficiency (Qualifier)
- drug effects (Qualifier)
- economics (Qualifier)
- genetics (Qualifier)
- history (Qualifier)
- immunology (Qualifier)
- isolation & purification (Qualifier)
- metabolism (Qualifier)
- pharmacokinetics (Qualifier)
- pharmacology (Qualifier)
- physiology (Qualifier)
- poisoning (Qualifier)
- radiation effects (Qualifier)
- standards (Qualifier)
- supply & distribution (Qualifier)
- therapeutic use (Qualifier)
- toxicity (Qualifier)
- ultrastructure (Qualifier)
- urine (Qualifier)
Action(s) pharmacologique(s)
Traductions
-
français
-
222535-22-0 (Alefacept)
-
ELK3V90G6C
-
Protéine de fusion LFA-3 IgG(1)
-
Protéine de fusion LFA-3 IgG1
URI
http://data.loterre.fr/ark:/67375/JVR-JZJQPKSH-H
{{label}}
{{#each values }} {{! loop through ConceptPropertyValue objects }}
{{#if prefLabel }}
{{/if}}
{{/each}}
{{#if notation }}{{ notation }} {{/if}}{{ prefLabel }}
{{#ifDifferentLabelLang lang }} ({{ lang }}){{/ifDifferentLabelLang}}
{{#if vocabName }}
{{ vocabName }}
{{/if}}